SAS Output

21-OCT-2018 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1312-ALL, CD22+, REL/REF, Inotuzumab+CVP 1 Y 1 CVP + Inotuzumab dose level 1 38 5 0 0 0 0 0 06/13/2014 3 3
        2 CVP + Inotuzumab dose level 2   5 0 0 0 0 0      
        3 CVP + Inotuzumab dose level 3   11 0 0 0 0 0      
        4 CVP + Inotuzumab dose level 4   5 0 0 0 0 0      
        5 CVP + Inotuzumab dose level 5   11 0 0 0 0 0      
        6 CVP + Inotuzumab MTD   8 8 7 5 3 0      
            45 8 7 5 3 0      
 
  S1318-ALL, Age 65+, Ph±, Blinatumomab 1 T 1 Induction: Ph- 44 31 0 0 0 0 0 06/30/2015 147 57
        2 Induction: Ph+/Ph-like   16 0 0 0 0 0      
            47 0 0 0 0 0      
 
    2 Y 3 Post-remission: Ph- 44 20 1 0 0 0 0 06/30/2015    
        4 Post-remission: Ph+/Ph-like   12 0 0 0 0 0      
            32 1 0 0 0 0      
 
    3 Y 5 Maintenance: Ph- 44 14 5 0 0 0 0 06/30/2015    
        6 Maintenance: Ph+/Ph-like   10 6 0 0 0 0      
            24 11 0 0 0 0      
 
  S1612-AML/MDS, Age 60+, Aza/Novel Therapeutics 1 Y 0 FLT3 Testing 1670 113 113 96 56 19 4 02/02/2018 233 92
            113 113 96 56 19 4      
 
    2 Y 1 Azacitidine 1670 26 26 19 12 4 0 02/02/2018    
        2 Azacitidine + Nivolumab   26 26 22 12 6 2      
        3 Azacitidine + Midostaurin   26 26 24 12 5 1      
            78 78 65 36 15 3      
 
  S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT 1 N 1 Induction/Consolidation 94 97 0 0 0 0 0 08/25/2010   9
            97 0 0 0 0 0      
 
    2 N 2 Vincristine/Pred/Dasatinib   22 0 0 0 0 0 08/25/2010    
            22 0 0 0 0 0      
 
    3 N 3 Allo stem cell transplant 37 43 0 0 0 0 0 08/25/2010    
            43 0 0 0 0 0      
 
    4 N 4 Dasatinib   42 0 0 0 0 0 08/25/2010    
            42 0 0 0 0 0      
 
Yes E1910-BCR-ABL-neg, B ALL, Blinatumomab 1 E Total Registrations   101 35 21 11 2 1 06/06/2014 1 83
            101 35 21 11 2 1      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 1 E Total Registrations   75 0 0 0 0 0 08/06/2012   71
            75 0 0 0 0 0      
 
No E1910-BCR-ABL-neg, B ALL, Blinatumomab 0 E Total Registrations   139 48 26 14 4 1 06/06/2014 1 83
            139 48 26 14 4 1      
 
    2 E Total Registrations   61 17 11 5 2 0 06/06/2014    
            61 17 11 5 2 0      
 
    3 E Total Registrations   47 10 7 4 1 1 06/06/2014    
            47 10 7 4 1 1      
 
    4 E Total Registrations   21 6 3 1 0 0 06/06/2014    
            21 6 3 1 0 0      
 
  E2906-AML, Age 60+, Clo vs Dauno+Cy 0 E Total Registrations   19 0 0 0 0 0 08/06/2012   71
            19 0 0 0 0 0      
 
    2 E Total Registrations   21 0 0 0 0 0 08/06/2012    
            21 0 0 0 0 0      
 
    3 E Total Registrations   11 0 0 0 0 0 08/06/2012    
            11 0 0 0 0 0      
 
  NHLBIMDS-LEUK, National MDS Study 1 E Total Registrations   18 13 8 2 1 0 12/22/2016 266 113
            18 13 8 2 1 0      
 

21-OCT-2018 6:10

LEUK Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1712 CML, chronic phase, TKI +/- Ruxolitinib 1 Randomization 20-Jul-18

21-OCT-2018 6:10

LEUK Recently Closed Studies Accrual Report

The REPORT Procedure

Detailed and/or summarized report

Table 1

OPEN Study Date
Closed
Reg. Arm Total
Regs
Regs
Last
30 Days
Regs
Last
7 Days
N S0805-Ph+ ALL, Dasatinib/CVAD +/- BMT 17-Oct-18 2 2 Vincristine/Pred/Dasatinib 22 0 0
      3 3 Allo stem cell transplant 43 0 0
      4 4 Dasatinib 42 0 0